Its lead product candidate includes plecanatide a phase 3 guanylate
cyclase C, or GC - C, receptor agonist, designed to treat GI disorders, primarily chronic idiopathic constipation, or CIC, and constipation - predominant irritable bowel syndrome, or IBS - C.
Activated heterotrimers have a wide array of effectors including adenylate
cyclase (AC), phospholipase
C - beta, PI 3 - kinases, GIRK channels and RhoA